According to Marcus Snow, MD, assistant professor of internal medicine in the division of rheumatology, University of Nebraska Medical Center, some of the most critical developments in the biosimilars space during 2017 were the result of payer decisions.
According to Marcus Snow, MD, assistant professor of internal medicine in the division of rheumatology, University of Nebraska Medical Center, some of the most critical developments in the biosimilars space during 2017 were the result of payer decisions.
CMS’ move to assign biosimilars unique reimbursement codes is a “big step,” according to Snow, but he also points to what he calls “a smaller development that signals that biosimilars may take longer than expected to have a market share"—the agreement between UnitedHealthcare and Janssen that resulted in the brand-name Remicade being made the payer’s preferred infliximab therapy. “While [the move] is not unexpected from a business sense, it did signal to all in rheumatology practice that biosimilars in the [United States] may have much slower uptake than many thought. It will be interesting to see how other payers adjust to competition in the biologic marketplace.”
Slow market entry and sluggish market uptake are cause for concern for Snow. “Amjevita (adalimumab-atto) will not be available until 2023 [in the United States] due to a legal settlement. It is FDA-approved, and many hoped it would be available in the near future but, it will not be available here for quite some time,” and even those therapies that have launched have struggled in the marketplace: “Inflectra has only reported about 2% of the market share despite being FDA approved and commercially available…which is maybe a bit surprising, but this demonstrates more of a formulary issue than lack of use or desire to use biosimilar infliximab by the treating rheumatologist.” Snow added that, “While the choice in treatment ideally would come out of a discussion between the treating provider and the patient, the decision regarding drug availability to the patient is made by the [pharmacy benefit manager] and the insurance company, not the healthcare provider.”
In 2018, Snow hopes to see a market entry for the first FDA-approved etanercept biosimilar, Erelzi, which he says “would probably be the most interesting biosimilar,” as it “would be the first available subcutaneous [anti—tumor necrosis factor] biosimilar in the rheumatology world, especially with the delay of Amjevita’s US debut…the availability of both drugs has been delayed due to legal challenges, but Erelzi is reported to be close to becoming available,” said Snow.
As rheumatologists wait for greater biosimilar availability, Snow reports that he sees increasing awareness of biosimilar therapies among his peers: “There is increased familiarity with biosimilars among rheumatologists, and this will keep growing in 2018. When [biosimilars] truly become available to the provider, trust in the biosimilars will grow quickly [as] the provider becomes more familiar with the drug.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.